CORT — Corcept Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $2.38bn
- $2.01bn
- $482.38m
- 93
- 37
- 63
- 69
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 306 | 354 | 366 | 402 | 482 |
Cost of Revenue | |||||
Gross Profit | 301 | 348 | 361 | 396 | 476 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 195 | 226 | 242 | 289 | 375 |
Operating Profit | 112 | 128 | 124 | 113 | 107 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 117 | 132 | 125 | 116 | 125 |
Provision for Income Taxes | |||||
Net Income After Taxes | 94.2 | 106 | 113 | 101 | 106 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 94.2 | 106 | 113 | 101 | 106 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 94.2 | 106 | 113 | 101 | 106 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.768 | 0.854 | 0.893 | 0.875 | 0.95 |